Sabine KnippSummaryAffiliation: Centre Hospitalier Universitaire Vaudois Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvementSabine Knipp
Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011, Lausanne, Switzerland
Leuk Res 31:1585-7. 2007..002 mg/l (0.027 micromol/l), both representing about 14% of blood levels. ATO thus crosses the blood-CSF-barrier when administered intravenously, but the concentration in CSF is probably not sufficient for treatment of meningeal leukemia...- Presence of peripheral blasts in refractory anemia and refractory cytopenia with multilineage dysplasia predicts an unfavourable outcomeSabine Knipp
Department of Haematology, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 44, 1011 Lausanne, Switzerland
Leuk Res 32:33-7. 2008..00005). Median survival of patients with PB was not different from that of RAEB I. We therefore propose to consider patients with PB, regardless of medullary blast, as RAEB I... - Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromesAkira Matsuda
Division of Hematology, Department of Internal Medicine, Saitama Medical School, 38 Morohongo, Moroyama, Iruma gun, Saitama, 350 0495, Japan
Blood 106:2633-40. 2005..In conclusion, our results indicate that the clinical features of Japanese patients with FAB-RA differ from those of German patients... - Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7Sabine Knipp
Haematologica 90:691-3. 2005..Long-term treatment with azathioprine seems to be associated with an increased risk of MDS and subsequent leukemic transformation... - Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypesSabine Knipp
Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
Cancer 110:345-52. 2007..It is unclear whether intensive chemotherapy is beneficial to patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) if they are aged >/=60 years... - Prospective validation of the WHO proposals for the classification of myelodysplastic syndromesUlrich Germing
Department of Hematology, Oncology and Clinical Immunology Heinrich Heine University Moorenstr 5, 40225 Dusseldorf, Germany
Haematologica 91:1596-604. 2006..The aim of this study was a prospective validation of the World Health Organization (WHO) proposals for the classification of myelodysplastic syndromes (MDS) with respect to their prognostic relevance... - Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDSAkos Czibere
Department of Haematology, Oncology and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
Br J Haematol 135:355-7. 2006..Addition of a specific JNK-inhibitor to Exisulind-treated advanced MDS and AML/MDS cells partly abrogated apoptosis. We propose that Exisulind is tested in clinical phase I/II trials for the treatment of advanced MDS and AML/MDS... - Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosisNorman Putzki
Department of Neurology, University Hospital Essen, Essen, Germany
Mult Scler 12:363-6. 2006..Cases suggest a time- and dose-dependent risk of sMDS in long-term therapy of MS with Aza. Long-term Aza therapy needs careful monitoring... - The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemiaAndrea Kuendgen
Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
Cancer 106:112-9. 2006..Valproic acid (VPA) inhibits histone deacetylase activity and, synergizing with all-trans retinoic acid (ATRA), achieves differentiation induction of myeloid blast cells in vitro... - Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemiaAndrea Kuendgen
Department of Hematology, Oncology, and Clinical Immunology, Heinrich Heine University, Dusseldorf, Germany
Ann Hematol 84:61-6. 2005..For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs. If patients relapse after an initial response to VPA, ATRA has the potential to induce a prolonged second response... - Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromesLuca Malcovati
Department of Hematology, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, 27100 Pavia, Italy
J Clin Oncol 25:3503-10. 2007....